Biomea Fusion, a clinical-stage company developing diabetes and obesity treatments, announced its management will participate in the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. The company will hold fireside chats and one-on-one meetings at both events in New York, providing updates on its oral therapies icovamenib and BMF-650. These presentations offer investors insight into Biomea's progress in addressing metabolic disorders, a significant global health challenge. Audio webcasts of the sessions will be available live and for replay on Biomea's website.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
